Plain-English translation of NCT05405868 on ClinicalTrials.gov ↗ ·
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether nicotinamide, a form of vitamin B3, can help slow vision loss in people with open-angle glaucoma. Glaucoma damages the nerve cells in the eye, gradually causing vision loss over time. Researchers believe this medication may help protect those nerve cells by improving how they use energy, potentially preserving your sight better than eye drops alone.
Currently, eye drops that lower eye pressure are the main treatment for glaucoma, but they don't work perfectly for everyone and many patients still lose vision over time. This trial exists to test whether this medication could offer an additional way to protect the eye's nerve cells and slow vision loss beyond what pressure-lowering drops can do.
You likely qualify if…
You likely don't qualify if…
You would first receive standard glaucoma eye drop treatment before the trial officially starts. Then you would be randomly assigned to receive either the medication or a matching placebo pill for up to 27 months. You would start with a lower dose for 6 weeks, then increase to the full dose. Throughout the trial, you would attend regular study visits where your vision and eye health would be monitored, and you would need to continue your eye drop treatment as directed.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
United Kingdom